Cargando…
Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
This commentary analyzes the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which has reported the cardiovascular benefits of liraglutide. It places the results of this seminal trial in the context of the evolution of diabetes care, compares t...
Autor principal: | Kalra, Sanjay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118235/ https://www.ncbi.nlm.nih.gov/pubmed/27613064 http://dx.doi.org/10.1007/s13300-016-0197-4 |
Ejemplares similares
-
LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations
por: Daniels, G H, et al.
Publicado: (2015) -
Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes
por: Kim, Hae Jin, et al.
Publicado: (2017) -
Liraglutide and Glycaemic Outcomes in the LEADER Trial
por: Zinman, Bernard, et al.
Publicado: (2018) -
Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial
por: Buse, John B., et al.
Publicado: (2020) -
Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial
por: Crowley, Matthew J., et al.
Publicado: (2020)